

Reflux oesophagitis

the role of gastric acid

Number 1
in a series

Healing

By its fundamental action in reducing both acidity and volume of gastric juice,¹ 'Tagamet' has been shown to achieve complete healing or marked improvement in the majority of patients with reflux oesophagitis.^{2,3} Overall experience in clinical trials,² has shown that, at the recommended dosage, 62% of 39 patients had complete healing or marked improvement compared with only 9% of 23 patients on placebo. Complete resolution of stricture, ulcers and erosions was also demonstrated in individual patients.



Symptomatic Relief

In one study³ most patients obtained rapid symptomatic improvement during 'Tagamet' treatment and within 4 weeks many were free from symptoms. A considerable reduction in the incidence of heartburn, reflux, dysphagia and odynophagia was also observed during therapy.

(Artist's impression of H₂ receptor antagonist acting on receptor site in the parietal cell in gastric mucosa.)

Tagamet



reduces gastric acid
secretion

References

1. Pharmacological evaluation of cimetidine, a new Histamine H₂-Receptor Antagonist. (1975) Brit. J. clin. Pharmacol. 2, 491.
2. Data on file (March 1977) Smith Kline & French.

3. Cimetidine in the treatment of oesophagitis. (1977) Proceedings of the Second International Symposium on Histamine H₂-Receptor Antagonists. Excerpta Medica, p. 297.

'Tagamet' (cimetidine) is available as 200mg film-coated tablets, 200mg/5ml syrup and 200mg/2ml ampoules. 'Tagamet' is a trade mark. Full prescribing information is available from:-

SK&F
a SmithKline company

Smith Kline & French Laboratories Limited
Welwyn Garden City
Hertfordshire AL7 1EY
Telephone: Welwyn Garden 25111

TC-AD18

ACTA GASTRO-ENTEROLOGICA BELGICA

Organe de la Société belge de Gastro-entérologie

SOMMAIRE du FASCICULE 9-10

Editorial: BROHEE, D. et DELCOURT, A. (Bruxelles). La macroamylasémie.

LIGNY, G. et SMETS, Ph. (Charleroi-Bruxelles). Relation entre la concentration acide du composant pariétal de la sécrétion gastrique et le débit acide maximal chez l'homme.

COLLARD, M. et REMY, P. (Montignies-le-Tilleul). Critères diagnostiques et tomодensitométrie du pancréas.

DELCOURT, A. (Bruxelles). La pancréatite biliaire.

BROHEE, D., NAEIJE, R., VAN MELSEN, A. et DELCOURT, A. (Bruxelles). La macroamylasémie.

SOMMAIRE du FASCICULE 11-12

BROECKAERT, I. et PLATTEBORSE, R. (Bruxelles). Une tumeur oesophagienne bénigne et asymptomatique constitue-t-elle une indication opératoire?

DAUBRESSE, J. C., MEUNIER, J. C. et LIGNY, G. (Charleroi). La stimulation de la sécrétion de prolactine par la cimétidine chez l'homme.

HELLER, F. et HARVENGT, C. (Louvain-en-Woluwe). La lithiase biliaire à cholestérol; physiopathologie et traitement.

SCHALM, S. W. (Rotterdam). Serum levels of chenodeoxycholic acid in health and non hepatic disease: relationship with cholelithiasis.

STALPORT, J. et RONSSE, G. (Huy). Les indications urgentes de la cholédocolithiase compliquée.

YVERGNEAUX, J. P., BAUWENS, E., VAN OUTRYVE, L. et YVERGNEAUX, E. (Gent). Etude de la papillo-infundibulotomie mesurée avec suture, à l'aide de la radiomanométrie et de la débit-métrie électronique. Etude préliminaire.

HOLLENDER, L. F., MEYER, Chr., CALDEROLI, H., DRYJSKI, J. et ALEXIU, D. (Strasbourg). Les perforations non traumatiques de l'intestin grêle en péritoine libre. Enseignement tiré d'une série de 13 cas.

DUMITRASCU, D., GRIGORESCU, M., ERDESY, St., SUCIA, A. et FODOR, O. (Cluj). Influence de l'antibiothérapie sur l'activité métabolique bactérienne dans les entéropathies.

Acta Gastro-enterologica Belgica: 6 fascicules doubles par an.


Abonnements (Belgique et Etranger): 1.500 Fr. b.

Le fascicule isolé: 250 Fr. b.

Secrétariat et rédaction: rue des Champs Elysées. 43. B 1050. Bruxelles. Belgique.

Chendol

A New Product
from British research
backed by nearly ten
years of clinical trial work.



Some stones you'd give a lot to own — others you'd rather lose.

Chendol capsules dissolve cholesterol gallstones

CHENDOL is a new form of medication developed by Weddel Pharmaceuticals to dissolve cholesterol gallstones over a period of time.

Results of recent studies have demonstrated a 93% success rate in the U.K.¹ and 81% in the U.S.A.² for dissolving cholesterol gallstones in patients with a functioning gallbladder.

INDICATIONS For dissolution of cholesterol gallstones in functioning gallbladders. Cholesterol stones coated with calcium, or stones comprised of bile pigments are not dissolved by chenodeoxycholic acid. It has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.

DOSAGE The present clinical evidence suggests that optimum results will be obtained on a dose level of 10–15 mg. per kg body weight daily in divided doses.

CONTRAINDICATIONS, WARNINGS, ETC. CHENDOL should not be administered to patients with radio-opaque calcified gallstones nor to patients with non-functioning

CHENDOL — chenodeoxycholic acid — reduces the amount of cholesterol secreted into the bile. Lithogenic bile becomes unsaturated and precipitated cholesterol is slowly dissolved.

gallbladders. In addition, at present CHENDOL should not be administered to women of child-bearing age, nor to patients with chronic liver disease, nor with inflammatory diseases of small intestine and colon.

CHENDOL is generally well tolerated; the only side effects reported to date are diarrhoea and pruritus. It has been found that after a slight reduction in dose for a few days diarrhoea ceases and the dose can then gradually be increased to the former level. Laboratory monitoring should accompany treatment.

Each Chendol capsule contains 125 mg of chenodeoxycholic acid.

Available in securitainers of 100 capsules. — N.H.S. cost £13.50 per pack.




Weddel
pharmaceuticals
limited

Red Willow Road,
Wrexham Industrial Estate,
Wrexham, Clwyd, LL13 9PX.

PL 0495/0003

Reference: 1. Maton, P. N., Iser, J. H., Murphy, G. M. and Dowling, R. H. Efficacy of withdrawal from and resistance to chenodeoxycholic acid treatment in patients with gallstones. *Gut*, 1977, 18, A976 (abstract).

2. Thistle, J. L., Hofmann, A. F., Ott, B. J. and Yu, P. Y. S. (1976). Gallstone dissolution with chenodeoxycholic acid 1969–1976: The Mayo Clinic Studies. *Gastroenterology*, 70, 943 (abstract).



Why Nalcrom should change your thinking about ulcerative colitis.

Prescribing Information

PRESENTATION: Nalcrom is a presentation of sodium cromoglycate for oral use. It is presented in clear/clear hard gelatine capsules printed Fisons 101 in black. Each capsule contains 100mg sodium cromoglycate as a white powder.

USES: As an adjuvant in the treatment of ulcerative colitis, proctitis and proctocolitis. Sodium cromoglycate is considered to exert a stabilising effect upon mast cells capable of releasing mediators, thus preventing the local inflammatory reaction in the gastrointestinal tract.

DOSAGE AND ADMINISTRATION: Dosage Adults: Two capsules four times daily.

Children: From 2-14 years; one capsule four times daily. Nalcrom should not be used for children under two years.

Maintenance dosage To prevent relapses dosage should be maintained indefinitely at two capsules four times daily in adults and one capsule four times daily in children.


Administration The capsules may be swallowed whole or alternatively the powder contents may be dissolved in 20-30ml of water and swallowed.

Nalcrom offers a completely new approach to the management of ulcerative colitis.

And it could mean freedom from side effects often associated with the limited number of treatments now available.

Nalcrom is sodium cromoglycate.

Sodium cromoglycate is the unique drug which is used successfully in the treatment of allergic diseases, such as asthma and rhinitis.




Sodium cromoglycate prevents the degranulation of mast cells caused by the interaction of antigens and reagin antibodies.

It is a potent inhibitor of mast cell degranulation. It prevents the release of inflammatory agents into sub-mucosal tissue in the lung, nose and other organs.

So it stops symptoms before they even start. And over ten years of clinical use have proved it to be a very effective drug with remarkably few serious side-effects.


Now it offers hope as a new treatment for ulcerative colitis.



On left mast cell undergoing gross degranulation. On right mast cell stabilised after treatment with sodium cromoglycate. Photomicrographs prepared by: R & D Laboratories, Fisons Ltd., Pharmaceutical Division.

Why an anti-allergy drug?

Ulcerative colitis in its natural history and histological appearance has many features such as macrophages, mast cells and eosinophils that suggest that an allergic or immunological process may be involved. Sodium cromoglycate may have a clinically beneficial effect in these processes. So a double blind cross-over trial was carried out with 26 patients suffering from chronic proctitis¹. The 14 responders to sodium cromoglycate had a high local eosinophil count which in most cases fell in the course of treatment.



In a double-blind cross-over trial of 26 patients, 14 responded to sodium cromoglycate, 10 didn't respond and 2 responded to placebo.

Another study of 12 patients with ulcerative colitis treated with sodium cromoglycate showed a significant improvement in sigmoidoscopic appearance. And again, rectal biopsies showed a significant reduction in eosinophil counts^{2,3}.

How to find out more about Nalcrom.

Specialist representatives are available at this stage to discuss Nalcrom with hospital doctors. Simply fill in and post the coupon or write to: Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

Nalcrom[®]
(Sodium Cromoglycate B.P.)

References 1. Heatley, R.V. et al, 1975, "Gut," **16**, 559 2. Mani, V. et al, 1976, "Lancet," **1**, 439 3. Mani, V. et al, 1977, "Gastro-enterology," **72**, 1093.

Please arrange for a specialist representative to call.

Name _____

Address _____

Further information is available on request from Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

FISONS[®]
Leaders in Allergy Research

GIN7

CONTRA-INDICATIONS, WARNINGS, ETC. Contra-indications There are no specific contra-indications. The safety of Nalcrom during pregnancy has not yet been established.

Side-effects Nausea has been reported in a few cases.

Overdosage As Nalcrom is absorbed only to a very limited extent, no action other than medical observation should be necessary.

PHARMACEUTICAL PRECAUTIONS: Store in a dry place. Reclose the container tightly after use.

LEGAL CATEGORY: P.O.M.

PACKAGE QUANTITIES: Containers of 100 capsules.

FURTHER INFORMATION: 1. Nalcrom may be used in conjunction with steroid therapy and sulphasalazine in the treatment of acute relapses of proctocolitis and in maintaining remissions.

2. If steroid therapy is to be reduced or withdrawn this should be done cautiously.

3. Nalcrom may be used in patients with a history of hypersensitivity to or intolerance of sulphasalazine.

4. Dosages of 2000mg daily have been used in some cases of proctocolitis.

PRODUCT LICENCE NUMBER: PL 0113/0073.

INTRALIPID* 10% INTRALIPID* 20%

Presentation

A milky white oil in water emulsion. Intralipid contains fractionated soya bean oil 10% or 20% emulsified with fractionated egg lecithin at pH 7. It also contains glycerol.

Indications: Intralipid fat emulsions are indicated in conditions of severe depletion requiring also a high energy intake to compensate for excessive loss of calories following trauma, infection, fever, burns, etc.

Dosage and Administration

500-1,500ml. daily in conjunction with intravenous amino-acids are administered by slow intravenous infusion.

Infant dosage: Intralipid 10% or 20%: 15-20ml. per kg. body weight in 24 hours.

Contra-indications

Intralipid is contra-indicated in pathological hyperlipaemia and severe liver damage.

Pharmaceutical Precautions

No drugs should be added to Intralipid prior to or during infusion.

Package Quantities

Intralipid 10%: 100ml. and 500ml.
Intralipid 20%: 100ml. and 500ml.

NHS Price:

£2.75, £6.50
£3.95, £9.55

Intralipid 10% Product Licence 0022/002/
Intralipid 20% Product Licence 0022/0028

VAMIN* GLUCOSE

Presentation

Clear, straw-coloured solutions for intravenous use containing all essential amino-acids, and a balanced mixture of non-essential amino-acids in each 1,000ml. (pH 5.2). Carbohydrate, as glucose (100g/l), has been added as an energy source. Electrolytes are present, but these may need supplementing according to patient needs.

Nitrogen per litre: 9.4g. corresponding to about 60g. of first-class protein. Caloric content per litre: 650 Kcal., of which 410 Kcal. are provided by glucose.

Uses

Vamin Glucose is indicated in conditions of protein depletion where oral or intragastric feeding is impossible or impracticable.

Dosage and Administration

Depending on the individual protein requirement, 0.5-2.0 litres intravenously per day.

Infant dosage: 30-40ml. per kg. body weight in 24 hours.

Contra-indications, Warnings, etc.

Irreversible liver damage and severe uraemia when dialysis facilities are not available. Care should be taken when administering this solution to diabetic patients.

Side effects: As with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used.

Package Quantities

Bottles of 100ml., 500ml. and 1,000ml.

NHS price:

£2.50, £6.75, £12.50

Product Licence 0022/0030

*Additives contain electrolytes, trace elements, fat soluble vitamins and water soluble vitamins for adults and children.

KabiVitrum 

Full prescribing information is available from KabiVitrum Ltd., Bilton House, Uxbridge Road, Ealing, London W5 2TH.



When you start to think about IV feeding...

.....make sure its complete and balanced, like a normal healthy diet. Intralipid and Vamin provide **all** the calories, **all** the essential fatty acids and **all** the nitrogen required for anabolism and recovery.

In addition there is now a range of additives specially tailored to meet the other nutritional requirements—vitamins, electrolytes and trace elements.

INTRALIPID VAMIN

NOW AVAILABLE—ADDITIVES*



the only nutritionally-complete recovery builders.



**In abdominal and
gynaecological surgery,
Flagyl is revolutionising
the treatment of infection...**


and now

Flagyl Injection

for intravenous infusion



M&B May & Baker



Flagyl

cause-specific,
effect...decisive

in most infections following abdominal
or gynaecological surgery

Most of these infections are caused by anaerobes

Post-operative infection is a major complication of gastro-intestinal and gynaecological surgery.¹ After colonic surgery the incidence can exceed 50 per cent.²

In both the colon and the female genital tract, non-sporing obligate anaerobic bacilli are commonly occurring (and, in the colon, heavily preponderant) organisms of the normal bacterial flora.²⁻⁴ Now, with greatly improved techniques of isolation, there is increasing awareness of their importance as the major pathogens in post-surgical infection involving these fields.^{1,2,4-7}

*"... it is now well established that most of these post-operative infections are due to anaerobes ..."*¹

*"... aerobic bacteria are usually only of secondary importance in these clinical settings."*²

Flagyl is specifically, intensely, consistently bactericidal to anaerobes...

'Flagyl' is unique as the only available antimicrobial agent with selective activity against obligate anaerobes.^{2,5} Experience shows it to be consistently, completely bactericidal to these organisms⁸ — at serum and tissue concentrations well below those normally obtained in treatment.^{1,7} Bactericidal concentrations are also rapidly reached in most other body fluids.¹

...and thus dramatically, uncompromisingly effective in clearing most of the infections

Incisively active against the primary pathogens, 'Flagyl' is spectacularly successful in providing effective antimicrobial therapy in most post-operative abdominal and gynaecological anaerobic infections.

"In all our infected patients the clinical and microbiological response to metronidazole was dramatic. Within 12-24 hours the

*temperature and pulse-rate had usually returned to normal, the patient looked and felt better... There was a strikingly rapid disappearance of anaerobic bacteria from pathological discharges, which ceased to be purulent and offensive and quickly subsided."*²

Even in cases of mixed anaerobic/aerobic aetiology, the use of 'Flagyl' alone, directed against the anaerobic component, has given excellent results.⁷

Moreover the results of preventative use are equally impressive:

*"... considerable reduction in post-operative morbidity due to metronidazole prophylaxis... has lightened the nursing of patients with serious post-operative sepsis by virtually eliminating it."*⁶

Flagyl does not have the drawbacks of agents previously used

Previously preferred antimicrobial agents such as chloramphenicol, lincomycin and clindamycin are not consistently bactericidal to anaerobes at readily attainable serum concentrations – nor completely bactericidal to all strains of the major species. They may also predispose to resistance of aerobic or facultatively anaerobic pathogens.^{4,5} 'Flagyl' reliably anaerobicidal and, through its specificity, incapable of inducing aerobic resistance,^{2,5,9} does not have these disadvantages – which is why it is now revolutionizing the management of post-operative abdominal and gynaecological infections.

Flagyl injection provides a convenient new dosage form for the seriously ill


'Flagyl' injection for intravenous infusion answers the need for conveniently given, rapidly effective medication for sepsis following major surgery,⁷ especially when the infection is well established. High blood levels can be very quickly obtained and adequately maintained¹⁰ until the patient is well enough to transfer to oral or rectal therapy.

*"We have found intravenous metronidazole to be safe, easy to administer, and well tolerated by patients..."*⁷

- ★ compatible in the body with other antibacterial agents when combined antimicrobial therapy is appropriate⁹
- ★ Seventeen years' well tolerated, widespread use in other major indications
- ★ now in oral, rectal and i.v. presentations

references and full prescribing information overleaf

Flagyl Injection



the vital complement
to surgical skill

Flagyl Injection

for intravenous infusion
in postoperative
abdominal and
gynaecological infection

PRESCRIBING INFORMATION (anaerobic infections)

N.B. Metronidazole has no useful direct activity against aerobic or facultatively anaerobic bacteria.

Presentation

Injection (for intravenous infusion) 0.5%w/v in 100ml bottles (500mg metronidazole per 100ml).

Uses

1. Treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly *Bacteroides fragilis* and other species of bacteroides and including other species for which metronidazole is bactericidal, such as fusobacteria, eubacteria, clostridia and anaerobic cocci.

'Flagyl' has been used successfully in: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis, peritonitis and postoperative wound infection, from which one or more of these anaerobes have been isolated.

2. Prevention of postoperative infections due to anaerobic bacteria, particularly species of bacteroides and anaerobic streptococci.

Dosage and Administration

In patients with severe anaerobic infection for whom oral medication is not possible or is contra-indicated, it is particularly useful in emergencies and is indicated in patients needing surgery who:

- have or are believed to have anaerobic sepsis such as septicaemia, peritonitis, subphrenic or pelvic abscesses.
- at operation show signs of established or impending anaerobic sepsis.
- undergo operations in which contamination occurs with anaerobes from the gastrointestinal or female genital tracts or the oropharynx.

In infants and other patients maintained on intravenous fluids, 'Flagyl' injection may be diluted with appropriate volumes of normal saline, dextrose-saline, dextrose 5% w/v or potassium chloride injections (20mmol and 40mmol).

1. Treatment:

Adults and children over 12 years:

100ml by intravenous infusion eight-hourly. The injection should be infused intravenously at the rate of 5ml per minute but may be administered alone or concurrently (but separately) with other bacteriologically appropriate antibacterial agents in parenteral dosage forms. Oral medication with 400mg three times daily should be substituted as soon as this becomes feasible. Treatment for seven days should be satisfactory for most patients but, depending upon clinical and bacteriological assessments, the physician might decide to prolong treatment e.g. for the eradication of infection from sites which cannot be drained or are liable to endogenous re-contamination by anaerobic pathogens from the gut, oropharynx or female genital tract.

Children under 12 years:

As for adults but the single intravenous dose is based on 1.5ml (7.5mg metronidazole) per kg bodyweight and the oral dose on 7.5mg per kg bodyweight.

2. Prevention:

Adults and children over 12 years:

100ml by intravenous infusion immediately before, during or after operation, followed by the same dose eight-hourly until oral medication (200 to 400mg three times daily) can be given to complete a seven-day course.

Children under 12 years:

As for adults but the single intravenous dose is based on 1.5ml (7.5mg metronidazole) per kg bodyweight and the oral dose on 3.7 to 7.5mg per kg bodyweight.

Contra-indications

There are no absolute contra-indications to the use of 'Flagyl' intravenous injection for anaerobic antibacterial therapy.

Precautions

The recommended dosages, frequencies of administration and durations of medication have been found effective and well tolerated in nearly all cases. However, regular clinical and biological surveillance are advised if administration of 'Flagyl' for more than 10 days is considered to be necessary.

Clinicians who contemplate continuous therapy, for the relief of chronic conditions, for periods longer than those recommended are advised to consider the possible therapeutic benefit against the risk of peripheral neuropathy.

Such evidence as is available suggests that patients with various degrees of renal impairment handle metronidazole like patients with normal renal function. Daily dosage may, however, be halved for patients with renal failure, if the clinician so wishes, as such dosage has been found effective.

Patients should be advised not to take alcoholic drinks during metronidazole therapy.

Metronidazole enhances the activity of warfarin and if 'Flagyl' is to be given to patients receiving this or other oral anticoagulants the dosages of the latter should be recalibrated.

Pregnant women tolerate metronidazole well and no adverse effect on their offspring has been reported. As with all medicines 'Flagyl' should not be given during pregnancy or during lactation unless the physician considers it essential.

Side effects and adverse reactions

No serious adverse reactions have been encountered with the recommended regimes. There have been occasional reports of an unpleasant taste in the mouth, furred tongue, nausea, vomiting (very rarely) and gastrointestinal disturbance. Drowsiness, dizziness, headache, ataxia, skin rashes, pruritus, inco-ordination of movement and darkening of the urine (due to a metronidazole metabolite) have been reported but very rarely. During intensive and/or prolonged metronidazole therapy, a few instances of peripheral neuropathy have been reported but in most cases the reaction disappeared after treatment was stopped or when dosage was reduced. A moderate leucopenia has been reported in some patients but the white cell count has always returned to normal before or after treatment has been completed. Transient epileptiform seizures have been reported in a few patients undergoing intensive, high-dosage metronidazole radio-sensitisation therapy.

Treatment of overdosage

There is no specific treatment for gross overdosage of 'Flagyl', but early gastric lavage is recommended. Uneventful recovery has followed attempts at suicide with quantities of 30 and 60 x 200mg tablets.

Pharmaceutical precautions

Protect from light.

Package quantities

Bottle of 100ml injection 0.5% w/v.

Further information

Other established indications for 'Flagyl' include urogenital trichomoniasis, giardiasis, all forms of amoebiasis, acute ulcerative gingivitis and acute dental infections. 'Flagyl' is also available as tablets and, in some territories, as suppositories.

References

- 1 *Scot. Med. J.*, 22, 155, 1977
- 2 *Br. Med. J.*, i, 607, 1977
- 3 *Finegold, S.M.*, Anaerobic bacteria in human disease, p. 257, Academic Press Inc., New York, 1977
- 4 *Lancet*, ii, 997, 1975
- 5 *S. Afr. Med. J.*, 52, 161, 1977
- 6 *Br. Med. J.*, i, 318, 1976
- 7 *Ibid.*, ii, 1418, 1976
- 8 *J. Infect. Dis.*, 131, 417, 1975
- 9 *J. Antimicrob. Chemother.*, 1, 387, 1975
- 10 *Selkon, J.B., Hale, J.H., Ingham, H.R.*, Chemotherapy, vol. 1, p. 277, Plenum Pub. Corp., New York, 1976.

'Flagyl' metronidazole

Tablets 200mg	PL 0012/5256
400mg	PL 0012/0084
Suppositories 500mg	PL 0012/0113
1gram	PL 0012/0114
Injection 0.5% w/v	PL 0012/0107

Further information is available on request
'Flagyl' is a trade mark
May & Baker Ltd Dagenham Essex RM10 7XS




M&B May & Baker

A member of the Rhône-Poulenc Group of Companies




Flagyl
the anaerobicide


Ulcer heal thyself!




Day 1 The liquid De-Nol flows into the empty stomach and duodenum and comes into direct contact with the ulcer. The active ingredient in De-Nol, a chelate, combines with the free amino acids and proteins at the ulcer site by secondary chelation. In this way a protective layer is formed.¹




Day 3 The protective coagulum defends the ulcer against both acid and pepsin. Early symptomatic relief is obtained and natural healing is obtained. De-Nol's therapeutic effect is localised rather than systemic. No serious side effects occur.



Day 28 A complete course of De-Nol lasts just 28 days. After this time it has been shown, endoscopically, that up to 90% of ulcers are completely healed.² A second course of De-Nol may occasionally be required, particularly in resistant cases.



Day 425 A recently published study² showed that in 83% (15 out of 18) of gastric ulcer patients successfully treated with De-Nol there had been no relapse within fourteen months (425 days).



De-Nol


Heals ulcers by helping them heal themselves

References: 1 Lavy et al, Archives Int. de Pharm. et la Therapie 224.2 1976. 2 Salmon et al, GUT 15,189 1974. 3 Lee & Nicholson., Med. J. Aust. 1977 1.808-812. De-Nol is a registered trademark. P/L No. 0166/5024

Full prescribing information is available upon request to

Brocades Great Britain Ltd.

Brocades House, Pyrford Road, West Byfleet, Weybridge, Surrey KT14 6RA Telephone: Byfleet 45536/42291 Telex: 917301



New!

The Esophagus Handbook and Atlas of Endoscopy

M. Savary G. Miller

KEITH S. HENLEY, MD.
GASTROENTEROLOGY
Vol. 73, No 4, Part 1, 860 (Oct. 1977):

As a "how to do it" book it is very good, and as a visual atlas it is superb...

This book is an asset to every department of endoscopy.

240 pages
310 full colors photographs, 71 drawings

This book is available in:

● **English**

Translation: D. Colin-Jones, Portsmouth
Foreword: A. Olsen, Rochester (Minn).
1978. ISBN 3-85698-0001-8. Swiss francs 180.-
(approx. \$ 98.-; £ 53.73 [5.4.78])

● **German**

Foreword: K. Heinkel, Stuttgart
1977. ISBN 3-85698-0001-8 SFr./DM 285.-

● **French**

Foreword: A. Naef, Yverdon.
1977. ISBN 3-85698-0001-8 SFr. 285.-

Distributors for USA and Canada:

TAG Photographic Inc.
800 Shames Drive
Westbury N. Y. 11590/USA



Please send me copy(ies) of:

Savary/Miller: **The Esophagus, Handbook and Atlas of Endoscopy**

(English/French/German Edition*)

Prices as above. On 20-day approval.

Save postage and handling by enclosing payment with your order.

Prices subject to change without notice.

Bill me Check enclosed

GASSMANN AG

Publishers

CH-4500 SOLOTHURN/Switzerland

Name _____

Full Address _____

NEW PYROGASTRONE

for positive healing and relief
of symptoms of oesophageal ulcers,
erosions and oesophagitis

PROTECTS against gastric and bile reflux

RELIEVES symptoms of reflux oesophagitis

HEALS by local actions of carbenoxolone

Chewable Pyrogastrone tablets form a viscous alginate antacid foam which soothes the mucosa, protects it from reflux, exerts a buffering effect against regurgitated acid and alkali, and helps to localise the action of low-dose carbenoxolone, the healing component.



In a recent study¹ Pyrogastrone was shown to give significantly better relief of symptoms of oesophagitis and healing of oesophageal ulcers than an alginate-antacid control containing no carbenoxolone*. In the authors' words, Pyrogastrone gave:

“...the most impressive results so far observed in the treatment of reflux oesophagitis.”¹

Presentation Each chewable, strawberry flavoured tablet contains Carbenoxolone Sodium B.P. 20mg, Magnesium Trisilicate B.P. 60mg and Dried Aluminium Hydroxide Gel B.P. 240mg in a base containing sodium bicarbonate B.P. and alginate acid B.P.C.

Pyrogastrone prescribing data

Indications Oesophageal inflammation, erosions and ulcers due to hiatus hernia or gastric reflux. Relief of heartburn, flatulence and other symptoms arising from these conditions. **Dosage** One tablet to be chewed three times daily immediately after meals and two tablets to be chewed at bedtime. **Length of treatment** Although Pyrogastrone quickly relieves symptoms, treatment should be continued for at least 6 weeks, but up to 12 weeks may be necessary to ensure maximum healing effect. **Contra-indications** Severe cardiac, renal or hepatic failure. Patients on digitalis glycosides (unless serum electrolyte levels are monitored regularly to detect development of hypokalaemia). **Precautions** Special care should be exercised with patients predisposed to sodium and water retention, potassium loss and hypertension (e.g. the elderly and those with cardiac, renal or hepatic disease) since the carbenoxolone

content of Pyrogastrone can induce similar changes. Regular monitoring of weight and blood pressure, which should indicate the development of such effects, is advisable for all patients. A thiazide diuretic should be administered if oedema or hypertension occurs (spironolactone should not be used because it hinders the therapeutic action of carbenoxolone). Potassium loss should be corrected by the administration of oral supplements. No teratogenic hazard is anticipated from the use of Pyrogastrone during pregnancy but careful consideration should be given before prescribing it for women who may become pregnant.

1. Study presented at the VIth World Congress of Gastroenterology, Madrid, June, 1978. *Both kinds of tablets used in this trial (active, 20 mg carbenoxolone; control, no carbenoxolone) contained only a third as much alginate and antacid as the Pyrogastrone tablets now available.

Pyrogastrone is made under licence from Biorex Laboratories Ltd., Brit. Pat. Nos. 843133 and 1390683. Pyrogastrone is a registered trade mark. Full information is available on request from Winthrop Laboratories, Surbiton-upon-Thames, Surrey.

WINTHROP



GEOFFREY'S REFINED HABITS HAVE LED TO A SERIOUS PROBLEM.

Many patients suffer from serious conditions such as haemorrhoids, diverticular disease, irritable colon or anal fissure, which may be associated with long standing dietary constipation.

These problems won't be resolved overnight. Fybogel, by quickly restoring natural fibre to the diet, relieves the constipation and rapidly improves the symptoms of the condition.




Fybogel sachets contain 3.5 g Ispaghula husk BPC.
Full prescribing information is available on request from
Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.
Fybogel is a registered trademark. PL No. 0044-0041. 1126





the natural way to end dietary constipation

NEW ENDOSCOPY EQUIPMENT AND TEACHING MODELS

**HEMISPHERIC ENDOSCOPY
TEACHING MODEL**



ENDOSCOPY TROLLEY



**SECURITY
ENDOSCOPY CABINET**

Please send for further details to:

Tillomed Laboratories Limited, Henlow Trading Estate, Henlow, Beds. Tel: 0462-813933

Made in England Overseas agencies available

Hypoxia and Ischaemia

*The Proceedings of a Symposium organized by the
Royal College of Pathologists*

Edited by Basil C. Morson

Factors influencing oxygen availability	I. MCA. LEDINGHAM
Local factors in tissue oxygenation	I. A. SILVER
The biochemical consequences of hypoxia	K. G. M. M. ALBERTI
Hypoxia and the pulmonary circulation	DONALD HEATH
Hypoxia and the carotid body	J. M. KAY AND P. LAIDLER
The pathology of myocardial ischaemia	M. J. DAVIES
Animal models of myocardial ischaemia	N. WOOLF
Responses of the splanchnic circulation to ischaemia	ADRIAN MARSTON
Ischaemic bowel disease	T. ALSCHIBAJA AND B. C. MORSON
Ischaemia of bone	MARY CATTO
Ischaemia of peripheral nerve and muscle	D. G. F. HARRIMAN
Hypoxia and tumours	R. H. THOMLINSON
The pathology of renal ischaemia	J. R. TIGHE
Renal necrosis	J. F. SMITH
The effects of hypoxaemia in fetal sheep	J. S. ROBINSON, C. T. JONES, AND G. D. THORBURN
Hypoxia in the newborn infant	E. O. R. REYNOLDS
Pathology of perinatal hypoxia	ALBERT E. CLAIREAUX
The concepts of thresholds of ischaemia in relation to brain structure and function	LINDSAY SYMON, N. M. BRANSTON, A. J. STRONG, AND T. D. HOPE
Structural abnormalities in neurones	A. W. BROWN
Pathology of hypoxic brain damage in man	D. I. GRAHAM
Experimental hypoxic brain damage	J. B. BRIERLEY

PRICE: Inland £5.00; Abroad US \$12.50 including postage

Payment must be enclosed with order or a surcharge of 30p will be made for rendering invoices and statements

This publication can be ordered now from

The Publishing Manager, JOURNAL OF CLINICAL PATHOLOGY
B.M.A. House, Tavistock Square, London WC1H 9JR

NUROLON* Braided Polyamide 66.

ETHICON
TRADEMARK



NUROLON* Braided Polyamide 66.

The synthetic suture that handles
with ease.

Yet, it will deliver all the advantages
you expect from a synthetic.

Compared to silk, there's less tissue
reaction. This is an advantage in intestinal
anastomosis and aids fine scars in skin
healing.

Stronger than silk in tissue, it ensures
long-term support in herniorrhaphy.

ETHICON

TRADEMARK

ETHICON Ltd., P.O. Box 408, Bankhead Avenue, Edinburgh EH11 4HE, Scotland.

Caved-S

**heals peptic ulcers
SAFELY**

Caved-S

**heals peptic ulcers
EFFECTIVELY**

Caved-S

**heals peptic ulcers
ECONOMICALLY**